Categories Analysis, Earnings, Retail

Beyond Meat Q1 earnings preview: It’s time to deliver

Thanks to the outlandish valuation on the stock, Beyond Meat (NASDAQ: BYND), has attracted a decent amount of short sellers in its few days of trading. According to the most recent reports, over 40% of its shares are currently being shorted. If the meat substitute company is hoping to make a point, the first quarter-earnings would be the right place and time.

Beyond Meat will report its maiden earnings results on Thursday, June 6, after the regular trading hours. Analysts have projected a loss of 15 cents per share on revenues of $40 million, which is almost half of what the company achieved in the whole of last year.

beyond meat revenue and operating income

For the time being, Wall Street may ignore the bottom-line figures: Beyond Meat is a budding company where cash is more likely to be used to drive growth than to just report profits. The top-line is where the company will need to deliver.

The stock has almost quadrupled since its IPO early last month, briefly breaching the $100 mark.  The positive rally was spurred by the company’s remarkable history of revenue growth and investor confidence in the alternate meat industry, which is set to grow at an annual rate of 40% over the next 10 years.  

READ: Why Beyond Meat valuation is beyond logic

Earlier today a report by the Wall Street Journal that stated that plant-based meat product manufacturers are struggling to meet the rising demand, spurred another stock rally.

Beyond Meat will emerge a winner if it delivers big on the top-line. If it also gives a full year guidance, it will be an icing on the cake.

The El Segundo, California-based company’s market cap is almost 70 times its 2018 full-year revenue, thus making the valuation beyond reason. Post the Q1 results, investors will be looking to find the reasons.   

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top